Suppr超能文献

肠道移植相关微血管病的临床病理表现及治疗

Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy.

作者信息

Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, Sawa M, Murata M, Nishiwaki S, Oba T, Yanada M, Naoe T, Ichihashi R, Fujino M, Yamaguchi T, Morishita Y, Hirabayashi N, Kodera Y, Miyamura K

机构信息

Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya 466-8560, Japan.

出版信息

Bone Marrow Transplant. 2009 Jul;44(1):43-9. doi: 10.1038/bmt.2008.419. Epub 2009 Jan 12.

Abstract

Intestinal transplant-associated microangiopathy (i-TAM) is an important complication after allogeneic hematopoietic SCT. From 1997 to 2006, 87 of 886 patients with diarrhea after transplantation received colonoscopic biopsy. i-TAM, GVHD and CMV colitis were diagnosed histopathologically. The median duration from transplantation to the onset of diarrhea was 32 days (range: 9-130 days) and that from the onset of diarrhea to biopsy was 12 days (range: 0-74 days). The median maximal amount of diarrhea was 2 l/day (range: 130-5600 ml/day). Histopathological diagnosis included i-TAM (n=80), GVHD (n=26), CMV colitis (n=17) and nonspecific findings (n=2) with overlapping. Among 80 patients with i-TAM, abdominal pain was a major symptom, and only 11 patients fulfilled the proposed criteria for systemic TAM. Non-relapse mortality (NRM) among patients without resolution of diarrhea was 72% and i-TAM comprised 57% of NRM. NRM was 25% among patients without intensified immunosuppression, but was 52, 79 and 100% among those with intensified immunosuppression before diarrhea, after diarrhea, and before and after diarrhea, respectively. In conclusion, i-TAM is a major complication presenting massive refractory diarrhea and abdominal pain, which causes NRM. Avoiding intensified immunosuppression that damages vascular endothelium until the resolution of i-TAM may improve transplant outcome.

摘要

肠道移植相关微血管病(i-TAM)是异基因造血干细胞移植后的一种重要并发症。1997年至2006年,886例移植后腹泻患者中有87例接受了结肠镜活检。通过组织病理学诊断出i-TAM、移植物抗宿主病(GVHD)和巨细胞病毒(CMV)结肠炎。从移植到腹泻发作的中位持续时间为32天(范围:9 - 130天),从腹泻发作到活检的中位持续时间为12天(范围:0 - 74天)。腹泻的最大中位量为2升/天(范围:130 - 5600毫升/天)。组织病理学诊断包括i-TAM(n = 80)、GVHD(n = 26)、CMV结肠炎(n = 17)和非特异性发现(n = 2)且存在重叠。在80例i-TAM患者中,腹痛是主要症状,只有11例符合系统性TAM的拟定标准。腹泻未缓解患者的非复发死亡率(NRM)为72%,其中i-TAM占NRM的57%。未强化免疫抑制的患者NRM为25%,但在腹泻前、腹泻后以及腹泻前后均强化免疫抑制的患者中,NRM分别为52%、79%和100%。总之,i-TAM是一种主要并发症,表现为大量难治性腹泻和腹痛,可导致NRM。在i-TAM缓解之前避免损害血管内皮的强化免疫抑制可能会改善移植结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验